LIF and metastatic neoplasm: Other baseline circulating miRNAs such as miR-143-3p, miR-197-3p, miR-223-3p, miR-223-5p, miR-338-3p, and miR-652-3p, as well as plasma LIF levels, are significantly higher in patients who develop secondary metastatic disease.